Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Holding(s) in Company

27 Jan 2011 16:55

RNS Number : 2273A
Avacta Group PLC
27 January 2011
 



TR-1: notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Avacta Group

2. Reason for the notification  (please tick the appropriate box or boxes)

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify): Increase in Issued Capital

X

3. Full name of person(s) subject to the notification obligation:

Universities Superannuation Scheme Ltd

4. Full name of shareholder(s) (if different from 3.):

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

26/01/11

6. Date on which issuer notified:

26/01/11

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details:

 

 

A: Voting rights attached to shares

Class/type of shares

 if possible using the ISIN CODE

Situation previous to the Triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights viii

Number of shares

Number of voting rights ix

% of voting rights

Direct

Direct x

Indirect xi

Direct

Indirect

Sedol:

3351954

45,166,666

 

45,166,666

 

45,166,666

 

45,166,666

2.763%

 

B: Financial Instruments

Resulting situation after the triggering transaction xii

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period/ Date xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

Total (A+B)

Number of voting rights

% of voting rights

 

45,166,666

 

2.763%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable xv:

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

Philip Brayne

15. Contact telephone number:

 0151 227 4711

 

Annex Notification Of Major Interests In Shares xvi

A: Identity of the person or legal entity subject to the notification obligation

Full name (including legal form for legal entities)

Universities Superannuation Scheme Ltd

Contact address (registered office for legal entities)

2nd Floor Royal Liver Building

Liverpool L3 1PY

Phone number

0151 227 4711

Other useful information (at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

Contact address

Phone number

Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

 

C: Additional information

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGZMVNDGMZM
Date   Source Headline
5th Jun 20267:00 amRNSOversubscribed Strategic Equity Fundraise of £9m
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.